Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.
GLOBETECH PUBLISHING

New Rapid Diagnostic Test Developed for Antibiotics Resistance

By Labmedica International staff writers
Posted on 08 Jul 2014
Image: Scanning electron micrograph of multidrug resistant Acinetobacter baumannii, a non-fermentative aerobic Gram-negative rod (Photo courtesy of Bioquell).
Image: Scanning electron micrograph of multidrug resistant Acinetobacter baumannii, a non-fermentative aerobic Gram-negative rod (Photo courtesy of Bioquell).
A rapid diagnostic test for multiresistance to broad-spectrum antibiotics has been developed for multidrug-resistant strains of Acinetobacter baumannii, an important hospital pathogen.

Bacterial resistance to antibiotics has increased considerably over recent years and the situation is particularly dramatic in regard to Gram-negative bacilli such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and A. baumannii, found in septicemic and abdominal infections and infections of the urinary tract and the lungs.

Microbiologists at the University of Fribourg (Switzerland) and their colleagues at Faculté de Médecine Paris-Sud, Le Kremlin-Bicêtre, France) collected a total of 220 strains to evaluate the performance of the CarbAcineto NP test. The strains included a collection of 151 carbapenemase-producing and 69 non-carbapenemase-producing Acinetobacter spp.

The test is based on the acidification properties generated by the enzymatic hydrolysis of a carbapenem, imipenem, when it is cleaved by a carbapenemase. The medium acidifies and the acidity indicator, which indicates pH, then turns from red to yellow. The detection of this carbapenemase activity can be realized by testing already isolated bacteria or any site infections. The result is obtained in less than two hours, while other techniques currently available require a minimum of 24 hours, most frequently 72 hours.

The specificity and of the CarbAcineto NP test were found to be 100% and the sensitivity was 94.7%. The CarbAcineto NP test efficiently detected OXA-type carbapenemase producers, leading to a significant improvement of the sensitivity to 94.7% for the CarbAcineto NP test versus 11.9% for the original Carba NP test. The use of the CarbAcineto NP test will be particularly important for intensive care unit (ICU) patients, for whom multidrug-resistant isolates belonging to the A. baumannii-A. calcoaceticus complex are a common source of severe infections. It specifically makes sense to test for carbapenemase production considering that the acquisition of a carbapenemase in A. baumannii is a marker of multidrug resistance.

The authors concluded that the CarbAcineto NP test is simple, cost-effective and, by detecting multidrug-resistant strains, it can prevent them spreading via outbreaks of hospital infections caused by multidrug-resistant bacteria, particularly among the most seriously ill patients and those undergoing resuscitation. This new test also provides a guide in the choice between the very few remaining treatment options for infected patients. Inserm Transfert (Paris, France) have filed an international patent for the CarbAcineto NP test. The study was published in the May 2014 issue of the Journal of Clinical Microbiology.

Related Links:

University of Fribourg
Faculté de Médecine Paris-Sud 
Inserm Transfert



EUROIMMUN AG
PURITAN MEDICAL
Sekisui Diagnostics
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: Enzyme-linked immunosorbent kit (ELISA) specific for human copeptin (Photo courtesy of USCN Life Science).

Preeclampsia Biomarker Detected Very Early In Pregnancy

A biomarker has been discovered that could give expecting mothers and their doctors the first simple blood test to reliably predict that a pregnant woman may develop preeclampsia, at least as early as... Read more

Pathology

view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

Brain Tumor Chemotherapy Biomarkers Identified

Cancer researchers have identified a new biomarker that they believe can predict whether glioblastoma multiformes (GBMs), the most common and aggressive type of malignant brain tumor, will be susceptible... Read more

Lab Tech.

view channel
Image: The ADVIA Centaur XPT Immunoassay System delivers the results that clinicians depend upon for accurate diagnoses and better patient care (Photo courtesy of Siemens Healthcare).

Introduction of New Central Laboratory Clinical Analyzers Highlights Recent Lab Equipment Exposition

An impressive array of new automated analyzers for central diagnostic laboratories was unveiled at a recent lab equipment trade fair. The IFCC WorldLab exposition held June 22-26, 2014, in Istanbul... Read more

Industry News

view channel

EKF Wins Distribution Contract and Regulatory Approval for Target Regions

EKF Diagnostics Holdings (Cardiff, Wales, UK), an AIM-listed point-of-care, central laboratory and molecular diagnostics business, announced that it has signed a new distribution contract in China and that one of its OEM (original equipment manufacturer) partners has received further regulatory approval across several target... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.